Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

NCT00863655 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

724

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Everolimus
DRUG: Exemestane
DRUG: Everolimus Placebo

Sponsor

Novartis Pharmaceuticals